BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
22 oct. 2024 00h30 HE | BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
RTI International and Codetta Bio™ announce strategic collaboration to accelerate healthcare innovation
15 oct. 2024 09h01 HE | Codetta Bio, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2024 (GLOBE NEWSWIRE) --  RTI International, a nonprofit research organization, and Codetta Bio™, an emerging leader in multi-omics for precision medicine, are...
Logo 1200x628.jpg
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07 août 2024 07h00 HE | CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
cmi_logo.png
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
28 mars 2024 15h30 HE | Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
Logo 400x400.jpg
CytoSorbents to Present at the 8th Annual Dawson James Conference
05 oct. 2023 07h00 HE | CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
Logo 400x400.jpg
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
11 sept. 2023 11h32 HE | CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
Logo 400x400.jpg
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
31 août 2023 07h00 HE | CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorbents New Logo - 2021.png
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
11 juil. 2023 07h00 HE | CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
inmunebio.jpg
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
24 mai 2023 09h00 HE | INmune Bio, Inc.
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) announces that Mark...
logo.png
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
08 mai 2023 08h00 HE | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...